中国肺癌杂志2012，Vol.15Issue(2)：106-111,6.DOI:10.3779/j.issn.1009-3419.2012.02.08
非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展
Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor Tvrosine Kinase Inhibitors in Non-small Cell Lung Cancer
李媛1
作者信息
- 1. 250117济南,山东省肿瘤医院内科,山东省医学科学院
- 折叠
摘要
Abstract
With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. However, the efficacy of EGFR-TKIs is limited by either primary (de novo) or acquired resistance after therapy. This review will focus on recently identified mechanisms of primary and acquired resistance to EGFR TKIs and strategies currently being employed to overcome resistance.关键词
表皮生长因子受体酪氨酸激酶抑制剂/肺肿瘤/耐药/机制Key words
Epidermal growth factor receptor-tyrosine kinase inhibitors/ Lung neoplasms/ Drug resistance/ Mechanism分类
医药卫生引用本文复制引用
李媛..非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展[J].中国肺癌杂志,2012,15(2):106-111,6.
